BioSpace News Archive

Data Provide Evidence of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy in Melanoma and in Combination With Pembrolizumab in Multiple Tumor Types

Seattle Genetics, Inc. and Astellas Pharma Inc. announced that a phase 3 trial of PADCEV® met its primary endpoint of overall survival compared to chemotherapy.

Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate

Phosplatin Therapeutics presented data from a Phase 1b dose escalation study of lead candidate PT-112, an immunogenic cell death inducer, used in combination with avelumab, a PD-L1 immune checkpoint inhibitor, in patients with progressing solid tumors who previously exhausted all available treatment options.

Successfully completed IPO in August 2020 raising $76.6 million in gross proceeds On track to initiate planned new clinical trials in melanoma and head and neck cancer

Deciphera Pharmaceuticals, Inc., announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors and intra-patient dose escalation data from the ongoing Phase 1 study of QINLOCK in patients with second-line through fourth-line plus GIST.

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, presented additional results from its pivotal Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer patients with HER2 exon 20 insertion mutations.

Five-year data from the SOLO-1 Phase III trial is the longest follow-up analysis for any PARP inhibitor in the 1st-line maintenance setting

Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) plus Yervoy®

Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will be added to the Russell 2000® Index, effective when the U.S. market opens on Friday, September 18, 2020.